Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxel- and carboplatin-based chemotherapy in an ovarian cancer patient: a case report and literature review.
Alkylating agents have strong leukemogenic potential. There are a number of recent acute myeloid leukemia (t-AML) cases related to previous paclitaxel exposure. These leukemias tend to be of aggressive subtypes with long-latency periods. Unlike previously reported cases, the present case was of the secondary acute megakaryoblastic myeloid leukemia (AML M7) subtype. Additionally, it did not harbor a translocation in chromosome 19. A 73-year-old woman was diagnosed with t-AML M7 with antecedent myelodysplasia. Leukemia followed a second induction of paclitaxel- and carboplatin-based chemotherapy for recurrent ovarian cancer. Her second induction began 25 months after completion of her first course of chemotherapy. The increased incidence of postpaclitaxel leukemia suggests a probable role for paclitaxel as a leukemogenic agent. It highlights the importance of assessing for leukemia risk factors prior to beginning paclitaxel therapy.
Yeasmin
S
S
Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Shimane, Japan.
Nakayama
K
K
Ishibashi
M
M
Oride
A
A
Katagiri
A
A
Purwana
I N
IN
Iida
K
K
Nakayama
N
N
Ishikura
H
H
Miyazaki
K
K
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D016190:Carboplatin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000139:chemically induced* / Q000150:complications* / Q000473:pathology; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000139:chemically induced* / Q000150:complications* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000627:therapeutic use*
D014408:Biomarkers, Tumor; D016190:Carboplatin; D017239:Paclitaxel